Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs

Abstract

BackgroundAdipose-derived mesenchymal stem cell (ADMSC) therapy in regenerative medicine is a rapidly growing area of research and is currently also being used to treat osteoarthritis (OA). Force platform analysis has been consistently used to verify the efficacy of different therapeutic strategies for the treatment of OA in dogs, but never with AD-MSC.The aim of this study was to use a force platform to measure the efficacy of intraarticular ADMSC administration for limb function improvement in dogs with severe OA.ResultsEight lame dogs with severe hip OA and a control group of 5 sound dogs were used for this study. Results were statistically analyzed to detect a significant increase in peak vertical force (PVF) and vertical impulse (VI) in treated dogs. Mean values of PVF and VI were significantly improved after treatment of the OA groups, reaching 53.02% and 14.84% of body weight, respectively, at day 180, compared with only 43.56% and 12.16% at day 0.ConclusionThis study objectively demonstrated that intraarticular ADMSC therapy resulted in reduced lameness due to OA.

Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man

“…The latter research group demonstrated considerable improvement in lameness and fewer signs of pain on range of motion after one month of treatment with MSCs in three dogs assessed by both a veterinarian and the owner, but no control group was used (Guercio et al 2012). The two former research groups reported comparable results for 18, 14 and 8 MSCstreated dogs, respectively, after a period of three or six months, compared to a placebo group that failed to improve (Black et al 2007;Black et al 2008;Vilar et al 2013). One other study dating also from 2008 demonstrated the successful clinical application of BM-derived canine MSCs for the treatment of some orthopaedic lesions in dogs: bone cyst of the glenoid, non-union of the tibia and femur, lengthening of the radius, large bone defect of the distal radius and Legg-Perth es-Calv e disease (Crovace et al 2008).…”

“…Black et al (2007Black et al ( , 2008, Vilar et al (2013) and Guercio et al (2012) evaluated the effects of canine MSCs on dogs affected by osteoarthritis of the coxofemoral joints and osteoarthritis of the humeroradial joints (Black et al 2007;Black et al 2008;Guercio et al 2012;Vilar et al 2013). The latter research group demonstrated considerable improvement in lameness and fewer signs of pain on range of motion after one month of treatment with MSCs in three dogs assessed by both a veterinarian and the owner, but no control group was used (Guercio et al 2012).…”

“…Therefore, MSCs hold great promise in this specific field. However, only a few studies exist on the use of MSCs for bone and cartilage problems in dogs and studies on the therapeutic applications of canine MSCs for tendon/ligament problems are even lacking (Bruder et al 1998;Barry & Murphy 2004;Black et al 2007;Black et al 2008;Hiyama et al 2008;Guercio et al 2012;Vilar et al 2013). Consequently, MSCs have sometimes been implemented without demonstrating their efficacy either in vitro or in preclinical animal models (Fortier & Travis 2011).…”

Intra-articular transplantation of porcine adipose-derived stem cells for the treatment of canine osteoarthritis: A pilot study

“…In veterinary medicine, there have been numerous claims in the mainstream media and in the Internet about ADSC's "miraculous" therapeutic efficacy. In the scientific literature, there have been four studies that used ADSCs to treat canine OA [12][13][14][15] , and the results all indicated ADSC's efficacy in ameliorating OA symptoms.…”

Effects of intra-articular injection of mesenchymal stem cells associated with platelet-rich plasma in a rabbit model of osteoarthritis

“…It is important to highlight that the current study aimed to use PRP as a vehicle for MSC application, and studies have found that multiple and sequential applications are required to obtain improvements in OA and chondral defects when using PRP alone (Khoshbin et al, 2013). Recent investigations have shown that growth factors found in the PRP function as carriers, and may enhance, stimulate, or even extend the effects of MSCs (Vilar et al, 2013). Factors such as TGF-b1, FGF, and PDGF were found to promote chondrogenesis and were also shown to be chondroprotective (Lee et al, 2010).…”